Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24101
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saad, Everardo D. | - |
dc.contributor.author | PAOLETTI, Xavier | - |
dc.contributor.author | BURZYKOWSKI, Tomasz | - |
dc.contributor.author | BUYSE, Marc | - |
dc.date.accessioned | 2017-08-07T09:10:07Z | - |
dc.date.available | 2017-08-07T09:10:07Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | NATURE REVIEWS CLINICAL ONCOLOGY, 14(5), p. 317-323 | - |
dc.identifier.issn | 1759-4774 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24101 | - |
dc.description.abstract | The advent of precision medicine has prompted profound changes in clinical cancer research, and the rising numbers of new therapeutic agents pose challenges in terms of the most appropriate trial designs and effects on the drug-approval process. In the past 5 years, some remarkably efficacious drugs have been approved based on evidence from uncontrolled phase I trials. We challenge the view that the expected benefits from new drugs are generally sufficient to forgo a randomized trial with patients assigned to a control arm (a regimen other than the experimental treatment). Relying on efficacy results from uncontrolled clinical trials can result in expedited drug approval, but the disadvantages of this practice must be taken into account. For example, the apparent improvements in outcomes observed in an early single-arm trial of a new therapy might reflect the prognostic nature of the target, rather than a true treatment effect. Moreover, the predictive role of biomarkers cannot be definitively ascertained without randomly assigning patients to a control arm. We discuss the need for such randomization to a true control in all phases of drug development and the role of companion biomarker testing. We propose that an increased use of randomization will facilitate a seamless transition between phases of drug and/or biomarker development. | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject.other | clinical trials; drug development; randomized controlled trials; statistical methods; targeted therapies | - |
dc.title | Precision medicine needs randomized clinical trials | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 323 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 317 | - |
dc.identifier.volume | 14 | - |
local.format.pages | 7 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Saad, Everardo D.; Burzykowski, Tomasz] IDDI, Ave Provinciale 30, B-1340 Ottignies, Belgium. [Paoletti, Xavier] Inst Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif, France. [Burzykowski, Tomasz] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I Biost, Martelarenlaan 42, B-3500 Hasselt, Belgium. [Buyse, Marc] Hasselt Univ, I BioStat, Martelarenlaan 42, B-3500 Hasselt, Belgium. [Buyse, Marc] IDDI, 185 Alewife Brook Pkwy,Suite 410, Cambridge, MA 02138 USA. | - |
local.publisher.place | NEW YORK | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1038/nrclinonc.2017.8 | - |
dc.identifier.isi | 000399452400009 | - |
item.validation | ecoom 2018 | - |
item.accessRights | Restricted Access | - |
item.fullcitation | Saad, Everardo D.; PAOLETTI, Xavier; BURZYKOWSKI, Tomasz & BUYSE, Marc (2017) Precision medicine needs randomized clinical trials. In: NATURE REVIEWS CLINICAL ONCOLOGY, 14(5), p. 317-323. | - |
item.fulltext | With Fulltext | - |
item.contributor | Saad, Everardo D. | - |
item.contributor | PAOLETTI, Xavier | - |
item.contributor | BURZYKOWSKI, Tomasz | - |
item.contributor | BUYSE, Marc | - |
crisitem.journal.issn | 1759-4774 | - |
crisitem.journal.eissn | 1759-4782 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
NRCO Precision medicine and randomized trials (1).pdf Restricted Access | Published version | 249.2 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
30
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
49
checked on May 8, 2024
Page view(s)
62
checked on Sep 6, 2022
Download(s)
54
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.